Six-Month Comparative Analysis Monitoring the Progression of the Largest Diameter of the Sweating Inhibition Halo of Different Botulinum Toxins Type-A

被引:8
作者
da Costa, Adilson [1 ]
Pegas Pereira, Elisangela Samartin [2 ]
Pereira, Margareth de Oliveira [2 ]
Calixto Dos Santos, Felipe Borba [2 ]
Favaro, Raquel [2 ]
de Matos, Lissa Sabino [2 ]
Tannous, Thaisa Saddi [2 ]
Parra Duarte, Carla Oliveira [3 ]
Pereira, Caroline Silva [2 ]
机构
[1] Inst Assistencia Med Ao Servidor Publ, Sao Paulo, SP, Brazil
[2] Pontifical Catholic Univ Campinas, Dept Dermatol, Campinas, SP, Brazil
[3] KOLderma Clin Trials Inst, Campinas, SP, Brazil
关键词
2 COMMERCIAL PREPARATIONS; DOUBLE-BLIND; COMPLEXING PROTEINS; FIELDS; BOTOX; HYPERHIDROSIS; MANAGEMENT; EFFICACY; DYSPORT; SAFETY;
D O I
10.1093/asj/sjy207
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Excessive sweating is a clinical condition that can be improved with type-A botulinum toxin (BTX-A). Objectives: To evaluate and compare the largest diameter of sweating inhibition halo (SIH) of 5 different commercially available BTX-A, in five different doses, in a 6-month-long clinical evaluation. Methods: Twenty-five adult female volunteers were injected in the dorsal trunk area with both 100 units (100UI) and 500 units (500UI) BTX-A products, reconstituted in a ratio of 1:2.5 IU, respectively. Products were applied in five different concentrations (1:2.5U, 2:5U, 3:7.5U, 4:10U, and 5:12.5U). After 30, 60, 90, 120, 150, and 180 days, a starch-iodine test was performed to obtain the largest diameter of each SIH. Results: The higher the number of units used, the larger the SIH p < 0.05 for all BTX-A. However, Botox (R), Botulift (R), Dysport (R), and Prosigne (R) have pretty likewise SIH along the study, with some few differences for some doses and months between one and another. However, Xeomin (R) is the BTX-A with the smallest SIH, in comparison with all others, in any dose and period. Conclusions: Differences were observed among all brands of BTX-As, based on dose and time after injection. Xeomin (R) provides the smallest SIH in comparison with others BTX-A.
引用
收藏
页码:993 / 1004
页数:12
相关论文
共 37 条
[11]   Focal hyperhidrosis: diagnosis and management [J].
Haider, A ;
Solish, N .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (01) :69-75
[12]  
HAMBLETON P, 1994, J ROY SOC MED, V87, P719
[13]   Botulinum toxin type A for aging face and aesthetic uses [J].
Hexsel, Camile ;
Hexsel, Doris ;
Porto, Manoela Donida ;
Schilling, Juliana ;
Siega, Carolina .
DERMATOLOGIC THERAPY, 2011, 24 (01) :54-61
[14]   A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A [J].
Hexsel, Doris ;
Dal'Forno, Taciana ;
Hexsel, Camile ;
do Prado, Debora Zechmeister ;
Lima, Maryelle Moreira .
DERMATOLOGIC SURGERY, 2008, 34 (01) :52-59
[15]   Fields of Anhidrotic Effects of AbobotulinumtoxinA in Patients With Compensatory Hyperhidrosis [J].
Hexsel, Doris ;
Soirefmann, Mariana ;
Porto, Manoela D. ;
Schilling-Souza, Juliana ;
Siega, Carolina .
DERMATOLOGIC SURGERY, 2015, 41 (01) :S93-S100
[16]   Fields of Muscular and Anhidrotic Effects of 2 Botulinum Toxin-A Commercial Preparations: A Prospective, Double-Blind, Randomized, Multicenter Study [J].
Hexsel, Doris ;
Soirefmann, Mariana ;
Porto, Manoela D. ;
Siega, Carolina ;
Schilling-Souza, Juliana ;
Rodrigues, Ticiana C. .
DERMATOLOGIC SURGERY, 2015, 41 (01) :S110-S118
[17]   Fields of Effects of 2 Commercial Preparations of Botulinum Toxin Type A at Equal Labeled Unit Doses A Double-blind Randomized Trial [J].
Hexsel, Doris ;
Hexsel, Camile ;
Siega, Carolina ;
Schilling-Souza, Juliana ;
Rotta, Francisco Telechea ;
Rodrigues, Ticiana C. .
JAMA DERMATOLOGY, 2013, 149 (12) :1386-1391
[18]   Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial [J].
Hexsel, Doris ;
Brum, Cristiano ;
do Prado, Debora Zechmeister ;
Soirefmann, Mariana ;
Rotta, Francisco Telechea ;
Dal'Forno, Taciana ;
Rodrigues, Ticiana C. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (02) :226-232
[19]  
Hexsel D, 2010, J DRUGS DERMATOL, V9, pS31
[20]  
Hexsel DM, 2009, ARCH DERMATOL, V145, P837, DOI 10.1001/archdermatol.2009.128